|
|
|
|
|
|
|
M T Wed Th F |
|
29 July, 2026 |
|
|
sponsored by
|
|
|
|
Making Waves in Peptide Synthesis
|
| Cambrex’s Chief Scientific Officer, Matt Bio, provides a forward-looking perspective on the forces reshaping peptide manufacturing, including handling of peptide fragments and supporting analytical activities. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Caldera-Synlogic and Vidya-Processa inked reverse mergers Wednesday, both backed by Bain. As Kyle LaHucik explains, companies increasingly see such listings as a fast way to gain cash and advance their drugs. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
A biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
💊 Atea Pharmaceuticals’ hepatitis C pill matches Gilead’s Epclusa: The biotech saidTuesday that its combination therapy of bemnifosbuvir and ruzasvir (BEM/RZR) hit
non-inferiority... | |
|
|
|
|
|
 |
|
Chris Gibson, Dimension Capital's new operating partner (Vaughn Ridley/Sportsfile for Web Summit via Getty Images) |
|
|
|
by Kyle LaHucik
|
In a decade of leading and building Recursion Pharmaceuticals, Chris Gibson attempted to bridge the worlds of biology and technology. Now, months after leaving Recursion... | |
|
|
|
|
|
|
by Max Gelman
|
Leqembi, the anti-amyloid Alzheimer’s drug from Eisai and Biogen, recorded $184 million in global sales in the second quarter, Biogen said Wednesday morning. It's the... | |
|
|
|
|
|
